These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 25753867)

  • 1. The comparison of microdose flare-up and multiple dose antagonist protocols based on hCG day estradiol (E2), progesterone (P) and P/E2 ratio among poor responder patients in ICSI-ET cycles.
    Cicek MN; Kahyaoglu I; Kahyaoglu S
    Eur Rev Med Pharmacol Sci; 2015 Feb; 19(4):539-44. PubMed ID: 25753867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microdose gonadotropin-releasing hormone agonist flare-up protocol versus multiple dose gonadotropin-releasing hormone antagonist protocol in poor responders undergoing intracytoplasmic sperm injection-embryo transfer cycle.
    Kahraman K; Berker B; Atabekoglu CS; Sonmezer M; Cetinkaya E; Aytac R; Satiroglu H
    Fertil Steril; 2009 Jun; 91(6):2437-44. PubMed ID: 18555238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The comparision of effect of microdose GnRH-a flare-up, GnRH antagonist/aromatase inhibitor letrozole and GnRH antagonist/clomiphene citrate protocols on IVF outcomes in poor responder patients.
    Ozcan Cenksoy P; Ficicioglu C; Kizilkale O; Suhha Bostanci M; Bakacak M; Yesiladali M; Kaspar C
    Gynecol Endocrinol; 2014 Jul; 30(7):485-9. PubMed ID: 24592985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of estradiol and progesterone priming/antagonist/letrozole and microdose flare-up protocols for poor responders undergoing intracytoplasmic sperm injection.
    Yucel O; Ekin M; Cengiz H; Zebitay AG; Yalcinkaya S; Karahuseyinoglu S
    Gynecol Endocrinol; 2014 Sep; 30(9):653-6. PubMed ID: 24850255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progesterone/estradiol ratio <0.25 on the day of human chorionic gonadotropin administration is associated with adverse pregnancy outcomes in prolonged protocols for in vitro fertilization/intracytoplasmic sperm injection.
    Li Y; Luo K; Tang Y; Lin G; Lu G; Gong F
    Taiwan J Obstet Gynecol; 2017 Feb; 56(1):27-31. PubMed ID: 28254221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of progesterone/estradiol ratio on pregnancy outcome of patients with high trigger-day progesterone levels undergoing gonadotropin-releasing hormone antagonist intracytoplasmic sperm injection cycles: a retrospective cohort study.
    Golbasi H; Ince O; Golbasi C; Ozer M; Demir M; Yilmaz B
    J Obstet Gynaecol; 2019 Feb; 39(2):157-163. PubMed ID: 30280612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minimal stimulation protocol using letrozole versus microdose flare up GnRH agonist protocol in women with poor ovarian response undergoing ICSI.
    Mohsen IA; El Din RE
    Gynecol Endocrinol; 2013 Feb; 29(2):105-8. PubMed ID: 23134528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GnRH antagonist administered twice the day before hCG trigger combined with a step-down protocol may prevent OHSS in IVF/ICSI antagonist cycles at risk for OHSS without affecting the reproductive outcomes: a prospective randomized control trial.
    Prapas Y; Ravanos K; Petousis S; Panagiotidis Y; Papatheodorou A; Margioula-Siarkou C; Iuliano A; Gullo G; Prapas N
    J Assist Reprod Genet; 2017 Nov; 34(11):1537-1545. PubMed ID: 28776117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparison of GnRH antagonist fixed protocol and GnRH agonists long protocol in infertile patients with normal ovarian reserve function in their first in vitro fertilization-embryo transfer cycle].
    Yang S; Chen XN; Qiao J; Liu P; Li R; Chen GA; Ma CH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Apr; 47(4):245-9. PubMed ID: 22781108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized controlled trial of gonadotropin-releasing hormone agonist microdose flare-up versus flare-up among poor responders undergoing intracytoplasmic sperm injection.
    Ghaffari F; Jahangiri N; Madani T; Khodabakhshi S; Chehrazi M
    Int J Gynaecol Obstet; 2020 Jan; 148(1):59-64. PubMed ID: 31569274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of LH, E2, and P level of HCG administration day on outcomes of in vitro fertilization in controlled ovarian hyperstimulation.
    Wei M; Zhang XM; Gu FL; Lv F; Ji YR; Liu KF; She H; Hu R
    Clin Exp Obstet Gynecol; 2015; 42(3):361-6. PubMed ID: 26152012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Supplementation with a recombinant human chorionic gonadotropin microdose leads to similar outcomes in ovarian stimulation with recombinant follicle-stimulating hormone using either a gonadotropin-releasing hormone agonist or antagonist for pituitary suppression.
    Cavagna M; Maldonado LG; de Souza Bonetti TC; de Almeida Ferreira Braga DP; Iaconelli A; Borges E
    Fertil Steril; 2010 Jun; 94(1):167-72. PubMed ID: 19342035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early Follicular Phase Human Chorionic Gonadotropin Addition May Improve the Outcomes of
    Zhang C; Wu F; Wu Z; Sun B; Chen C; Qian W
    Front Endocrinol (Lausanne); 2021; 12():739773. PubMed ID: 34707571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of microdose flare-up and antagonist multiple-dose protocols for poor-responder patients: a randomized study.
    Demirol A; Gurgan T
    Fertil Steril; 2009 Aug; 92(2):481-5. PubMed ID: 18990368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of the effects of three luteal phase support protocols with estrogen on in vitro fertilization-embryo transfer outcomes in patients on a GnRH antagonist protocol.
    Scheffer JB; Scheffer BB; Carvalho RF; Aguiar AP; Lozano DHM; Labrosse J; Grynberg M
    JBRA Assist Reprod; 2019 Aug; 23(3):239-245. PubMed ID: 30875186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Basal serum progesterone and history of elevated progesterone on the day of hCG administration are significant predictors of late follicular progesterone elevation in GnRH antagonist IVF cycles.
    Venetis CA; Kolibianakis EM; Bosdou JK; Lainas GT; Sfontouris IA; Tarlatzis BC; Lainas TG
    Hum Reprod; 2016 Aug; 31(8):1859-65. PubMed ID: 27301360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The value of the progesterone-to-estradiol ratio on the day of hCG administration in predicting ongoing pregnancy and live birth rates in normoresponders undergoing GnRH antagonist cycles.
    Cetinkaya ES; Berker B; Aytac R; Atabekoglu C; Sonmezer M; Ozmen B
    Eur J Obstet Gynecol Reprod Biol; 2013 Oct; 170(2):452-7. PubMed ID: 23932375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploration of the value of progesterone and progesterone/estradiol ratio on the hCG trigger day in predicting pregnancy outcomes of PCOS patients undergoing IVF/ICSI: a retrospective cohort study.
    Yang Y; Liu B; Wu G; Yang J
    Reprod Biol Endocrinol; 2021 Dec; 19(1):184. PubMed ID: 34893087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of LH supplementation to the GnRH antagonist protocol in advanced reproductive ageing women: a prospective randomized controlled study.
    Younis JS; Izhaki I; Ben-Ami M
    Clin Endocrinol (Oxf); 2016 Jan; 84(1):99-106. PubMed ID: 26304041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stop GnRH-Agonist Combined With Multiple-Dose GnRH-Antagonist Protocol for Patients With "Genuine" Poor Response Undergoing Controlled Ovarian Hyperstimulation for IVF.
    Orvieto R; Kirshenbaum M; Galiano V; Elkan-Miller T; Zilberberg E; Haas J; Nahum R
    Front Endocrinol (Lausanne); 2020; 11():182. PubMed ID: 32528403
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.